TY - JOUR
TI - Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis
AU - Rizos, E.D.
AU - Antonogiannaki, E.-M.
AU - Chatzidakis, A.
AU - Kallieri, M.
AU - Tsilogianni, Z.
AU - Manali, E.D.
AU - Economopoulos, N.
AU - Triantafyllou, K.
AU - Papiris, S.A.
AU - Polymeros, D.
JO - European Journal of Gastroenterology and Hepatology
PY - 2021
VL - 33
TODO - 1S Suppl 1
SP - e1057-e1059
PB - NLM (Medline)
SN - 0954-691X, 1473-5687
TODO - 10.1097/MEG.0000000000002197
TODO - null
TODO - Vedolizumab, an anti-integrin antibody, is effective for moderate to severe ulcerative colitis and Crohn's disease treatment with a good safety profile due to its gut selective mechanism of action. Upper respiratory tract vedolizumab adverse events are common; however, they are mild and do not require treatment withdrawal. Herein, we present a 39-year-old patient under vedolizumab treatment for ulcerative colitis who presented acute severe interstitial lung injury that necessitated vedolizumab withdrawal and systemic steroids administration. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
ER -